The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Treatment options for patients with AML that are not candidates for intensive chemotherapy
In this video, Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, shares her insights into the therapeutic options available for patients with acute myeloid leukemia (AML) that are not candidates for intensive chemotherapy. First, Dr Patel discusses the importance of looking at factors such as age and biology of disease when determining whether patients are candidates for intensive chemotherapy. Following this, Dr Patel explains that based on data from the VIALE-A and VIALE-C trials, hypomethylating agent (HMA)-based therapy with venetoclax or low-dose cytarabine plus venetoclax is the upfront treatment option for these patients. To conclude, Dr Patel mentions that other novel combination therapies including checkpoint inhibitors are where this field is headed. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
Disclosures
BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.
